Skip to main content
. Author manuscript; available in PMC: 2018 Feb 9.
Published in final edited form as: Mol Cancer Ther. 2016 Aug 15;15(11):2598–2608. doi: 10.1158/1535-7163.MCT-16-0106

Figure 5. Pharmacological inhibition of metastatic colonization by (1b).

Figure 5

(A) Bioluminescence images of NSG mice injected IC with HDQ-P1-Luc cells at t=1h and 24h after injection. At 2h after injection mice were treated with vehicle, (1b) (40 mg/kg) IP Q12h or trametinib (tram) (2 mg/kg) IP Q24h. Inhibition of RSK or MEK decreases total metastatic burden (B) and the number of metastatic foci in individual organs (t=24h) (C). Bar, mean ± SD (n=4 mice/group, *p<0.05). (D) Inhibition of RSK or MEK decrease total metastatic burden (t=6d). (n=4 mice/group). Representative ex vivo bioluminescence images of livers (E) and adrenal glands (G) (t=6d). Ex vivo analysis confirms that inhibiting RSK or MEK activity decreased the metastatic burden in livers (F) and adrenals (H). (n=4 mice/group).